skip to content

Broker Views

Broker Forecast - Goldman Sachs issues a broker note on Hikma Pharmaceuticals PLC

22 August 2017 09:20

Goldman Sachs today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to neutral (from buy) and cut its price target to 1310p (from 2600p).

Story provided by StockMarketWire.com

Related Company: HIK

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.